124 related articles for article (PubMed ID: 38592381)
21. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
[TBL] [Abstract][Full Text] [Related]
22. Predictor factors for conservative management of cervical intraepithelial neoplasia grade 2: Cytology and HPV genotyping.
Salvadó A; Miralpeix E; Solé-Sedeno JM; Kanjou N; Lloveras B; Duran X; Mancebo G
Gynecol Oncol; 2021 Sep; 162(3):569-574. PubMed ID: 34226019
[TBL] [Abstract][Full Text] [Related]
23. Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K; Shabalova I; Sarian L; Naud P; Longatto-Filho A; Derchain S; Kozachenko V; Zakharchenko S; Roteli-Martins C; Nerovjna R; Kljukina L; Tatti S; Branovskaja M; Branca M; Grunjberga V; Erzen M; Juschenko A; Serpa Hammes L; Podistov J; Costa S; Syrjänen S; ;
Eur J Gynaecol Oncol; 2012; 33(1):5-14. PubMed ID: 22439398
[TBL] [Abstract][Full Text] [Related]
24. Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: a review.
de Witte CJ; van de Sande AJ; van Beekhuizen HJ; Koeneman MM; Kruse AJ; Gerestein CG
Gynecol Oncol; 2015 Nov; 139(2):377-84. PubMed ID: 26335596
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.
Apter D; Wheeler CM; Paavonen J; Castellsagué X; Garland SM; Skinner SR; Naud P; Salmerón J; Chow SN; Kitchener HC; Teixeira JC; Jaisamrarn U; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Mindel A; de Sutter P; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Clin Vaccine Immunol; 2015 Apr; 22(4):361-73. PubMed ID: 25651922
[TBL] [Abstract][Full Text] [Related]
26. Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.
Perez S; Iñarrea A; Pérez-Tanoira R; Gil M; López-Díez E; Valenzuela O; Porto M; Alberte-Lista L; Peteiro-Cancelo MA; Treinta A; Carballo R; Reboredo MC; Alvarez-Argüelles ME; Purriños MJ
Virol J; 2017 Nov; 14(1):214. PubMed ID: 29110680
[TBL] [Abstract][Full Text] [Related]
27. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
28. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
[TBL] [Abstract][Full Text] [Related]
29. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G;
Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373
[TBL] [Abstract][Full Text] [Related]
30. Local applications of GM-CSF induce the recruitment of immune cells in cervical low-grade squamous intraepithelial lesions.
Hubert P; Doyen J; Capelle X; Arafa M; Renoux V; Bisig B; Seidel L; Evrard B; Bousarghin L; Gerday C; Boniver J; Foidart JM; Delvenne P; Jacobs N
Am J Reprod Immunol; 2010 Aug; 64(2):126-36. PubMed ID: 20367631
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
[TBL] [Abstract][Full Text] [Related]
32. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
[TBL] [Abstract][Full Text] [Related]
33. Expression of p16
Badiga S; Chambers MM; Huh W; Eltoum IA; Piyathilake CJ
Cancer; 2016 Dec; 122(23):3615-3623. PubMed ID: 27479745
[TBL] [Abstract][Full Text] [Related]
34. Comparison of human papillomavirus distribution in cytologic subgroups of low-grade squamous intraepithelial lesion.
Zuna RE; Wang SS; Schiffman M; Solomon D
Cancer; 2006 Oct; 108(5):288-97. PubMed ID: 16952155
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
[TBL] [Abstract][Full Text] [Related]
36. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
[TBL] [Abstract][Full Text] [Related]
38. CK7 Immunohistochemistry as a Predictor of CIN1 Progression: A Retrospective Study of Patients From the Quadrivalent HPV Vaccine Trials.
Mills AM; Paquette C; Terzic T; Castle PE; Stoler MH
Am J Surg Pathol; 2017 Feb; 41(2):143-152. PubMed ID: 27680604
[TBL] [Abstract][Full Text] [Related]
39. The impact of epithelial biomarkers, local immune response and human papillomavirus genotype in the regression of cervical intraepithelial neoplasia grades 2-3.
Ovestad IT; Gudlaugsson E; Skaland I; Malpica A; Munk AC; Janssen EA; Baak JP
J Clin Pathol; 2011 Apr; 64(4):303-7. PubMed ID: 21421698
[TBL] [Abstract][Full Text] [Related]
40. Molecular progression to cervical precancer, epigenetic switch or sequential model?
Nedjai B; Reuter C; Ahmad A; Banwait R; Warman R; Carton J; Boer S; Cuzick J; Lorincz AT
Int J Cancer; 2018 Oct; 143(7):1720-1730. PubMed ID: 29679470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
